Kansas is currently home to 882 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/28/2025
Locations: Alliance for Multispecialty Research Newton, Newton, Kansas
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Register for Updates
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/28/2025
Locations: Alliance for Multispecialty Research Newton, Newton, Kansas
Conditions: Obesity
Register for Updates
Neuroimaging of Escitalopram in Autism Spectrum Disorder
NCT06826326
Recruiting
The goal of this clinical trial is to evaluate the acute effects of escitalopram (Lexapro®) on select brain networks during task-based functional magnetic resonance imaging (fMRI) in adolescent individuals with autism spectrum disorder (ASD). We hope to learn more about the acute effects of escitalopram and how it might be used to treat inflexible thinking or rigid-compulsive behavior that can be associated with restricted and repetitive behaviors in adolescents with ASD. Participants will: *... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/28/2025
Locations: Hoglund Biomedical Imaging Center, Kansas City, Kansas
Conditions: Autism Spectrum Disorder
Register for Updates
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485
Recruiting
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: The University of Kansas Cancer Center - Westwood, Westwood, Kansas
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985
Recruiting
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Hepatocellular Carcinoma
Register for Updates
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
NCT06619561
Recruiting
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Kansas Cancer Center-Westwood, Westwood, Kansas
Conditions: Chronic Graft-Versus-Host Disease (cGVHD)
Register for Updates
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT06568172
Recruiting
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses hig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Resectable Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129
Recruiting
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/28/2025
Locations: The University of Kansas Cancer Center - Westwood, Westwood, Kansas
Conditions: Large B-cell Lymphoma
Register for Updates
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: The University of Kansas Cancer Center - Westwood, Westwood, Kansas
Conditions: Multiple Myeloma
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/28/2025
Locations: Akero Clinical Study Site, Topeka, Kansas
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
NCT06168942
Recruiting
The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: The Kansas City Heart Rhythm Institute, Overland Park, Kansas
Conditions: Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Register for Updates
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390
Recruiting
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Kansas Clinical Research Center, Fairway, Kansas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates